GSK
740 hedge funds and large institutions have $9.83B invested in GSK in 2017 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 288 increasing their positions, 251 reducing their positions, and 71 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
740
Holders Change
-38
Holders Change %
-4.88%
% of All Funds
18.48%
Holding in Top 10
10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-9.09%
% of All Funds
0.25%
New
42
Increased
288
Reduced
251
Closed
71
Calls
$130M
Puts
$79M
Net Calls
+$50.7M
Net Calls Change
-$19.1M
Top Buyers
| 1 |
Dodge & Cox
San Francisco,
California
|
+$602M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$132M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$101M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$39.1M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$34.2M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$208M |
| 2 |
Millennium Management
New York
|
-$94.9M |
| 3 |
HA
Homestead Advisers
Arlington,
Virginia
|
-$79.9M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$49.9M |
| 5 |
Jane Street
New York
|
-$33M |
